Chairs: John Gribben and Paolo Ghia
After participating in this broadcast you should be able to:
- Describing key considerations when selecting first-line treatment for patients with CLL.
Chair: John Gribben
Current and future options - Carol Moreno
Practical management/optimising outcomes - George Follows
After participating in this broadcast you should be able to:
- Discuss recent clinical data relating to the management of patients with relapsed/refractory CLL.
Chair: John Gribben
AML and MDS: what's new from ASH 2018? - Valeria Santini
After participating in this broadcast you should be able to:
- Predict whether recent clinical data relating to AML and MDS will impact daily clinical practice.
Chair: John Gribben
Key trends and updates from ASH 2018 for B-cell lymphomas - Christian Buske
Update on mantle cell lymphoma - Simon Rule
Update on Waldenström's macroglobulinemia - Steven Treon
After participating in this broadcast you should be able to:
- Identify how recent clinical data relating to B-cell lymphomas could potentially impact daily clinical practice.
Chairs: John Gribben and Jesús San Miguel
After participating in this broadcast you should be able to:
- Describe the current and potential future role of CAR T cells in the management of a range of haematological malignancies.
Chair: Jesús San Miguel
What's new from ASH 2018? - Efstathios Kastritis
After participating in this broadcast you should be able to:
- Discuss recent clinical data relating to amyloidosis.
Chair: Jesús San Miguel
After participating in this broadcast you should be able to:
- Describe key considerations when selecting first-line treatment for patients with previously untreated MM.
Chair: Jesús San Miguel
After participating in this broadcast you should be able to:
- Discuss data from ASH 2018 relating to the management of previously treated MM and its potential impact on daily clinical practice.